NextCure Q2 2022 Earnings Report
Key Takeaways
NextCure reported its second quarter 2022 financial results, highlighting upcoming clinical data updates for NC318, NC410, and NC762 programs, as well as an IND filing for NC525. The company's cash position was reported as $185.5 million as of June 30, 2022, which is expected to fund operations into the first quarter of 2024.
Set the stage for multiple clinical data updates in the second half of this year for NC318, NC410, and NC762 programs.
IND filing for NC525 is expected.
Cash position of $185.5 million as of June 30, 2022.
Existing cash is expected to fund operations into the first quarter of 2024.
NextCure
NextCure
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into the first quarter of 2024.